It was at the end of June, 2019 that Umeå-based UmanDiagnostics merged with its largest customer and partner – leading American life science company Quanterix. In November the same year the company signed a licensing and delivery agreement with global giant Siemens Healthineers.
“Our goal is to give patients with neurological disorders a better quality of life. Thanks to our new partnerships we are expanding globally,” says Niklas Norgren.
UmanDiagnostics has recently recruited yet another employee to its offices in Umeå. Joakim Vickman, who joins from Swetree Technologies, has been appointed Production Technician.
“We are delighted Joakim has joined us. His appointment strengthens our team and prepares us for a rise in orders,” says Niklas Norgren.
“I’m really looking forward to developing professionally and will bring enthusiasm and experience from my previous posts to my new role. It’s great to be a part of the company’s future,” says Joakim Vickman.
UmanDiagnostics was founded in 2006 by Niklas Norgren and Torgny Stigbrand and is located at the Umeå Biotech Incubator. From the outset the company has worked with nerve injury markers and the protein NF-light. NF-light is found in nerve cells. If nerves become damaged due to a trauma or neurological disease the protein leaks into the cells’ surroundings. Thanks to UmanDiagnostics’ nerve marker a simple blood test measures how much of the NF-light protein has leaked out, which helps indicate how significant any damage may be.
“When we teamed up with Quanterix we gained access to their marketing and sales department, which has given us a major boost. We enjoy the backing of strong and committed owners, which ensures our continued presence in Umeå,” says Niklas Norgren.
A total of nine people are now employed at UmanDiagnostics in Umeå. The company was awarded both the Technology Award of the Year and Spin-Off Company of the Year at Umeågalan in November, 2019.
For further information please contact:
Niklas Norgren, CEO at UmanDiagnostics
090-77 78 80
UmanDiagnostics is committed to delivering fast and accurate diagnosis of neurological diseases. The company develops and markets valuable tools for early detection of diseases, measuring treatment efficacy and monitoring of disease progression. The company was founded in 2006 and since then has focussed on diseases affecting white matter such as Multiple Sclerosis, Alzheimer’s Disease and Amyotrophic Lateral Sclerosis.